Log in

goodpods headphones icon

To access all our features

Open the Goodpods app
Close icon
headphones
ReachMD CME

ReachMD CME

ReachMD

Your professional development is critical to the care of your patients. Stay on top of the latest treatments and information with ReachMD's CME activities. Our topics span cardiology, diabetes, oncology, cardiology, women's health and more. And our CME library is continuously growing, every quarter.
bookmark
Share icon

All episodes

Best episodes

Top 10 ReachMD CME Episodes

Goodpods has curated a list of the 10 best ReachMD CME episodes, ranked by the number of listens and likes each episode have garnered from our listeners. If you are listening to ReachMD CME for the first time, there's no better place to start than with one of these standout episodes. If you are a fan of the show, vote for your favorite ReachMD CME episode by adding your comments to the episode page.

CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-is-the-impact-of-first-line-pnh-treatment-choice-on-risk-of-thrombosis/16113/

This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/sleep-architecture-and-neurotransmitters-of-sleep/16181/

Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.

bookmark
plus icon
share episode
ReachMD CME - Patient Perspective: Living With Insomnia
play

09/29/23 • 0 min

CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/patient-perspective-living-with-insomnia/16182/

Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/exploring-the-impact-of-insomnia-on-daytime-functioning-and-cognition/16183/

Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.

bookmark
plus icon
share episode
ReachMD CME - Utilizing Assessment Tools in Insomnia
play

09/29/23 • 0 min

CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/utilizing-assessment-tools-in-insomnia/16184/

Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/examining-treatment-options-for-insomnia-from-orexin-to-gaba/16185/

Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 29-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/integrating-evidence-and-cultural-sensitivity-in-patient-centric-insomnia-treatments/16186/

Insomnia is characterized by difficulty falling asleep, staying asleep, and experiencing non-restorative or poor-quality sleep; it often leaves individuals feeling unrefreshed upon awakening. Symptoms during the day may include fatigue, irritability, impaired focus, and excessive sleepiness. The condition can significantly deteriorate a person’s quality of life, leading to reduced productivity, impaired cognitive function, mood disturbances, and an increased risk of accidents or injuries due to daytime sleepiness.
This educational program delves into the pathophysiology and diagnosis of insomnia as well as the role of the orexin system in the sleep/wake cycle. The program also evaluates the latest treatments, including the dual orexin receptor antagonists (DORAs), daridorexant, and lemborexant, and how these DORAs compare to other insomnia treatments with the aim of improving treatment choices, reducing adverse events, and improving patient outcomes.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c3-inhibitor-treatment-of-pnh/16111/

This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/is-long-term-complement-inhibition-safe-and-effective-in-pnh/16114/

This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.

bookmark
plus icon
share episode
CME credits: 0.75
Valid until: 22-09-2024
Claim your CME credit at https://reachmd.com/programs/cme/what-are-the-data-supporting-first-line-c5-inhibitor-treatment-of-pnh/16112/

This program provides awareness for practitioners to correctly diagnose Paroxysmal Nocturnal Hematuria (PNH) due to overlap with other diseases, which often causes a delay in diagnosis. The approval of the first complement inhibitor changed the outlook for people with PNH dramatically, yet today, two-thirds to 80% of patients on anti-C5 therapy still suffer from anemia. Approximately a fourth of patients continue to experience breakthrough hemolysis, a loss of disease control that greatly increases the risk of thrombosis. New treatments are tackling those challenges with different approaches to complement inhibition. This program provides an awareness of managing treatment-related adverse events associated with complement inhibitors. In addition, this program focuses on how healthcare providers can best serve their patients by increasing their confidence in knowing how to discern the differences in new therapeutics available and select the optimal first line regimen best suited for their patients with PNH to increase their quality of life.

bookmark
plus icon
share episode

Show more best episodes

Toggle view more icon

FAQ

How many episodes does ReachMD CME have?

ReachMD CME currently has 1781 episodes available.

What topics does ReachMD CME cover?

The podcast is about Health & Fitness, Medicine, Podcasts and Science.

What is the most popular episode on ReachMD CME?

The episode title 'Expert Answers to Common Questions for Who’s at Risk? Preventing and Managing Tumor Lysis Syndrome and Neutropenia in CLL' is the most popular.

When was the first episode of ReachMD CME?

The first episode of ReachMD CME was released on Dec 14, 2018.

Show more FAQ

Toggle view more icon

Comments